Popular Articles From: Exact Sciences Offers Update on Cologuard’s® Early Launch Trajectory to Final 2014 Desktop Online Holiday Sales Reach $53.3 Billion, Up 15 Percent vs. Year Ago

Exact Sciences Corp.
Sign-up for Exact Sciences Offers Update on Cologuard’s® Early Launch Trajectory investment picks
Exact Sciences Corp.
Sign-up for Exact Sciences: Additional Update on CMS Reimbursement for Cologuard® investment picks
Exelixis, Inc. (NASDAQ:EXEL) today announced that it has extended and restructured its agreement with Swedish Orphan Biovitrum AB (Sobi) to support the distribution and commercialization of COMETRIQ ® (cabozantinib) for progressive, unresectable, locally advanced or metastatic medullary thyroid cancer (MTC) in the European Union (EU), Switzerland, Norway, Russia, and Turkey.
Sign-up for Exelixis and Swedish Orphan Biovitrum AB (Sobi) Extend and Restructure Distribution Agreement for COMETRIQ® for Medullary Thyroid Cancer investment picks
Exelon today issued the following statement on the State of Illinois report on potential nuclear power plant closings prepared in response to House Resolution 1146: We thank the state for its attention and work on such an important issue for Illinois and the future of the state’s energy assets.
Sign-up for Exelon Statement on Illinois Nuclear Power Plant Report investment picks
ST. LOUIS , Jan.
Sign-up for Express Scripts Announces Fourth Quarter 2014 Earnings Conference Call and Webcast of Investor Day Meeting investment picks
By Joseph Walker The largest manager of U.S. prescription-drug benefits is taking sides in a fight between new hepatitis C treatments that cost close to $100,000 per patient.
Sign-up for Express Scripts picks AbbVie over Gilead for hepatitis C drug investment picks
Iconic Fashion Retailer Teams up with Golden State Warrior in a New Brand Ambassador Role NEW YORK , Dec.
Sign-up for EXPRESS, Inc. Signs NBA Super Star Stephen Curry investment picks
http://www.marketwire.com/library/MwGo/2015/1/15/11G030529/Extendicare_Inc.-1387207530938.jpg MARKHAM, ON--(Marketwired - January 15, 2015) - Extendicare Inc. ("Extendicare" or the "Company") (TSX: EXE) announced today that the Company has entered into a definitive agreement to acquire the Revera Home Health business from Revera Inc. (the "Vendor"), for $83 million in cash, before working capital adjustments (the "Transaction"). The completion of the Transaction is subject to customary closing conditions and regulatory approvals, including assignment of government contracts, and is expected to close following receipt of regulatory approvals.
Sign-up for Extendicare Announces Significant Acquisition to Expand its Canadian Home Health Care Business investment picks
The big drop in oil prices may be good for the consumer, and therefore the broader economy, but it's bad enough for Exxon Mobil (XOM) and Chevron (CVX) to tip Dow Jones Industrial Average futures prices into negative territory early Friday.
Sign-up for Exxon, Chevron stock selloffs turning Dow futures negative investment picks
Exxon Mobil Corp.
Sign-up for Exxon's 2015 capex plan to be revelead next month investment picks
Adding Secure WiFi™ for in-store convenience and advanced analytics ATLANTA , Dec.
Sign-up for Fabric and Crafts Retailer Hancock Fabrics Enhances Customer Shopping Experience and Security with EarthLink Comprehensive Managed Network and Security Solution investment picks
Sign-up for Facebook to Announce Fourth Quarter and Full Year 2014 Results investment picks
NORWALK, Conn., Jan.
Sign-up for FactSet Releases New Fixed Income Ownership Feed investment picks
Sign-up for Fannie Mae Releases November 2014 Monthly Summary investment picks
ARCHBOLD, Ohio , Dec.
Sign-up for Farmers & Merchants Bancorp, Inc. Declares 4th Quarter Dividend investment picks
By Peter Loftus AbbVie's Viekira Pak, a cocktail of several drugs, cured more than 90% of most common form of hepatitis C U.S. regulators on Friday approved AbbVie Inc.'s new multidrug regimen for hepatitis C, the latest in a wave of new medicines that is transforming treatment of the liver disease.
Sign-up for FDA approves AbbVie's hepatitis treatment investment picks
BLINCYTO is the First-and-Only Bispecific CD19-Directed CD3 T-Cell Engager (BiTE®) Immunotherapy to be Approved by the FDA BLINCYTO (Blinatumomab) for Injection Will be Available as a 35 mcg Single use Vial THOUSAND OAKS, Calif.
Sign-up for FDA Approves BLINCYTO™ (Blinatumomab) Immunotherapy for the Treatment of Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia investment picks
By Ron Winslow U.S. regulators Monday approved Bristol-Myers Squibb Co.'s Opdivo for advanced skin cancer, the latest drug to reach the market in the emerging field of cancer immunotherapy.
Sign-up for FDA approves Bristol-Myers's skin cancer treatment Opdivo investment picks
Sign-up for FDA Grants Soligenix "Fast Track" Designation for SGX301 for the First-Line Treatment of Cutaneous T-Cell Lymphoma investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1166852&ProfileId=051205&sourceType=1 NASHVILLE, TN --
Sign-up for Federal Bureau of Prisons Elects Not to Renew Contract at the Northeast Ohio Correctional Center investment picks
Netlist Wins Major Legal Victory in Trade Secret, Breach of Contract Lawsuit Against Diablo Technologies, Inc. in Case Involving ULLtraDIMM SSD In Rare Step, Federal Court Orders a Preliminary Injunction Against Diablo Technologies and its Controller Chips Used in Products by SanDisk, IBM, Lenovo, Huawei, and Supermicro OAKLAND, Calif.
Sign-up for Federal Court Orders Halt to Sales of New High-Speed Computer Chips Used by SanDisk, IBM and Other OEMs investment picks
- Expands Federated's line of liquid alternative strategies - Complements $2 billion alternative and objective-based product line PITTSBURGH , Jan.
Sign-up for Federated Investors, Inc. Launches Managed Volatility Fund, Building on Experience with Outcome-based Products investment picks
Ferro Corporation (NYSE: FOE, “Company”) announced today that it has completed the sale of the majority of the assets of its Polymer Additives business to Polymer Additives, Inc., a wholly owned portfolio company of H.I.G. Capital, LLC, for approximately $154 million in cash, subject to customary working capital and other purchase price adjustments.
Sign-up for Ferro Announces the Sale of Its North America-Based Polymer Additives Business investment picks
Combines strengths in fraud management and financial crime prevention & compliance to address expanding global market for integrated, enterprise-class, risk-based solutions SAN JOSE, Calif.
Sign-up for FICO Acquires TONBELLER investment picks
DES MOINES, Iowa , Jan.
Sign-up for Fidelity & Guaranty Life To Report Fiscal 2015 First Quarter Financial Results On February 4, 2015 investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1165846&ProfileId=051205&sourceType=1 LAS VEGAS, NV and MOUNTAIN VIEW, CA --
Sign-up for FIDO Ready(TM) Products at the 2015 International Consumer Electronics Show investment picks
DIRECTV will host the crown jewel of Super Bowl parties on Saturday, Jan.
Sign-up for Fifth Annual DIRECTV Super Saturday Night to Feature Rihanna investment picks
Spending in Final Week of the Season Pushes Totals to Slightly Beat Forecast Cyber Monday Ranks as Heaviest Spending Day of the Season for 5th Consecutive Year RESTON, Va.
Sign-up for Final 2014 Desktop Online Holiday Sales Reach $53.3 Billion, Up 15 Percent vs. Year Ago investment picks
Premium Membership: Features and Benefits
Wide-Moat Screener for Stocks

Put a moat around your portfolio. Sniff out the most promising opportunities that can ride through any market.

Gold Medalist Screener for Funds

Narrow the available universe of 5000 funds to the top rated gold and silver. Then, sort for manager tenure, expense ratio, risk and return to create your own index-beating fund watchlist.

Thousands of Premium Analyst Reports

While many of our competitors measure a stock's worth with a computer program, Morningstar's staff of 150+ analyst sift through company fillings, financial data and a wealth of other sources to deliver an unvarnished review of any investment. In fact, twelve Morningstar analysts have been recognized by WSJ as "Best on the Street" in the US.

Premium Portfolio Monitor

Make decisions with confidence. Load your investments into our research center and automatically connect to all our proprietary tools and data points.


Never be without critical research. Free with your active membership, take our Premium data and guidance wherever you go with Morningstar for iPad®, iPhone®, and Android apps.

Morningstar's Guarantee

We're looking out for you. If after your 14-day free trial, you find that a Morningstar Premium membership is not for you, cancel any time and we'll be happy to refund the unused portion - no questions asked.

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Popular Articles From: Exact Sciences Offers Update on Cologuard’s® Early Launch Trajectory to Final 2014 Desktop Online Holiday Sales Reach $53.3 Billion, Up 15 Percent vs. Year Ago
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent